VEGFA and acute myeloid leukemia: Since VEGF signals via receptor tyrosine kinases (RTKs) with the intracellular signaling cascade, TKIs (tyrosine kinase inhibitors) are a family of small molecules that are under clinical investigation for AML treatment with relevance to angiogenesis (e.g., semaxanib, sunitinib, or sorafenib).